Top Industry Leaders in the Merkel Cell Carcinoma Market
Latest Merkel Cell Carcinoma Treatment Companies Updates:
October 2023, Argenx, a Belgian biotech company, submitted an MAA to the European Medicines Agency (EMA) for ARGX-110, a novel investigational antibody-drug conjugate for treating metastatic MCC. This marks a significant step towards potential approval and wider availability of the therapy.
November 2023, Blueprint Medicines, a precision oncology company, presented positive Phase 2 data for avapritinib, a targeted therapy for patients with advanced MCC harboring the PI3K pathway mutation. The data showed promising overall survival and response rates, paving the way for further clinical development.
November 2023, Iovance Biotherapeutics, a clinical-stage biotechnology company, announced the initiation of a Phase 3 trial evaluating Iovance-018, a tumor-infiltrating lymphocyte (TIL) therapy, for the first-line treatment of metastatic MCC. This large-scale study aims to confirm the efficacy and safety of this personalized immunotherapy approach.
December 2023, Merck and Moderna entered into a strategic collaboration to develop personalized mRNA vaccines for MCC. This partnership combines Merck's expertise in oncology with Moderna's mRNA technology platform, aiming to create vaccines tailored to individual patients' tumor mutations.
List of Merkel Cell Carcinoma Treatment Key companies in the market:
- Merck & Co.
- OncoSec Medical Incorporated (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- General Electric Company (U.S.)
- Siemens Medical Solutions USA CANON MEDICAL SYSTEMS CORPORATION
